Is Certolizumab Pegol an Effective Longterm Maintenance Treatment for Moderate to Severe Crohn's Disease?
نویسندگان
چکیده
منابع مشابه
is certolizumab pegol safe and effective in the treatment of patients with moderate to severe crohn’s disease? a meta-analysis of controlled clinical trials
conclusions cp is effective for inducing clinical response and maintenance of clinical remission in patients with moderate to severe cd with similar side-effect profile as the control arms. background tumor necrosis factor-α (tnf-α) antibodies are currently used in patients with moderate to severe crohn’s disease (cd) who are unresponsive to conventional therapies. certolizumab pegol (cp) is on...
متن کاملIs Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials
BACKGROUND Tumor necrosis factor-α (TNF-α) antibodies are currently used in patients with moderate to severe Crohn's disease (CD) who are unresponsive to conventional therapies. Certolizumab pegol (Cp) is one of the anti-TNF-α agents introduced for the management of CD and rheumatoid arthritis. OBJECTIVES The aim of this meta-analysis is to assess the efficacy of Cp in inducing clinical respo...
متن کاملEndoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
OBJECTIVE To evaluate the efficacy of certolizumab pegol (CZP) in improving endoscopic lesions in patients with active ileocolonic Crohn's disease (CD). METHODS This phase IIIB multicentre open-label clinical trial enrolled 89 adult patients with active endoscopic disease (ulceration in ≥2 intestinal segments with a Crohn's Disease Endoscopic Index of Severity (CDEIS) score ≥8 points). Patien...
متن کاملCertolizumab pegol for the treatment of Crohn's disease.
In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate ...
متن کاملCertolizumab pegol in the treatment of Crohn's disease.
INTRODUCTION The introduction of antibodies directed against tumour necrosis factor (anti-TNF) has dramatically changed the concept of treating patients with Crohn's disease (CD). Unfortunately, the long-term efficacy of anti-TNF agents may be hampered by immunogenicity. The availability of more anti-TNF agents in the therapeutic armamentarium would therefore be of great benefit in patients loo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Gastroenterology
سال: 2011
ISSN: 1598-9992
DOI: 10.4166/kjg.2011.58.2.121